시장보고서

상품코드

1535259

녹내장 치료제 시장 : 규모 및 예측, 세계와 지역 점유율, 동향, 성장 기회 분석 리포트 : 약제 클래스별, 적응증별, 유통 채널별, 지역별

Glaucoma Therapeutics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Indication, Distribution Channel, and Geography

발행일: 2024년 07월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 150 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

녹내장 치료제 시장은 2023년에 62억 4,000만 달러로 평가되며, 2031년에는 80억 2,000만 달러에 달할 것으로 예측되며, 2023-2031년 CAGR은 3.2%로 추정됩니다.

시장 성장을 가속하는 주요 요인은 녹내장 유병률 증가, 녹내장에 대한 인식 증가 및 조기 진단, 제품 출시 증가가 시장 성장을 가속할 것으로 예상됩니다. 그러나 투약 계획 준수 문제와 높은 치료 비용으로 인해 녹내장 치료제 시장의 성장을 저해하는 요인으로 작용하고 있습니다.

녹내장 치료제 시장 동향 :

녹내장이라는 안질환은 주로 노화로 인한 안압 상승으로 인해 시신경이 서서히 손상되어 결국에는 돌이킬 수 없는 실명에 달할 수 있는 질환입니다. 녹내장의 가장 일반적인 치료법 중 하나는 안약을 사용하여 안압을 낮추는 것입니다. 그러나 환자들의 안약 복용 순응도가 낮고, 환자 교육이 충분하지 않으면 치료의 성공을 방해할 수 있습니다. 또한 안압 강하제는 국소 및 전신 부작용을 유발할 수 있으며, 치료를 더욱 복잡하게 만들 수 있습니다. 안정성 향상, 순환 시간 연장, 표적 결합 특성 등을 갖춘 개량형 제제 시장 개척에 관심이 집중되고 있으며, 새로운 제품이 시장에 진입할 가능성이 높습니다. 최근 녹내장 치료제의 발전은 시중에 나와 있는 녹내장 치료제에 혁명을 불러일으키고 있습니다. 적절한 구조와 우수한 결합 능력을 가진 나노입자의 사용은 약물의 생체 이용률과 효능을 촉진합니다. 서방형(SR) 임플란트 및 기타 혁신적인 약물전달 시스템은 기존 점안제 대비 환자의 순응도를 개선하고 부작용을 감소시키며, POAG 치료의 장벽을 극복할 수 있으므로 여러 회사가 국소 투여를 대체할 수 있는 SR 약물전달 시스템을 개발하고 있습니다. 2022년 PubMed Central에 게재된 논문에 따르면 미국 식품의약국(FDA)이 POAG에 대해 승인한 유일한 SR 요법은 아라간의 비마토프로스트 SR(DurystaTM)입니다. 비마토프로스트 아이링(Allergan), iDose(Glaukos Corporation), ENV515(Envisia Therapeutics), OTX-TP(Ocular Therapeutix), OTX-TIC(Ocular Therapeutix), 라타노프로스트 유리산 SR(PolyActiva)을 포함한 다른 SR 요법은 현재 연구 중이며, POAG 관리에서 SR 약물전달 기술은 치료 패러다임을 바꾸고 치료 결과를 획기적으로 개선할 수 있는 잠재력을 가지고 있습니다. 따라서 새로운 약물전달 방법과 병용요법의 개발은 녹내장 치료제 시장의 주요 동향이 될 것으로 보입니다.

녹내장 치료제 시장 부문별 개요

녹내장 치료제 시장은 약품 유형별, 적응증별, 유통 채널별로 구분됩니다.

약물 유형에 따라 시장은 베타 차단제, 알파 아드레날린 작용제, 프로스타글란딘 유사체, 탄산탈수효소 억제제, 복합제, 기타로 나뉘며, 2023년에는 프로스타글란딘 유사체 부문이 더 큰 시장 점유율을 차지할 것으로 예상됩니다. 프로스타글란딘 아날로그는 녹내장 환자의 안압이 높은 경우 1차 선택 치료제로 사용됩니다. 프로스타글란딘 유사체는 1일 1회 투여로 안압을 크게 낮추고 전신 부작용이 적습니다. 따라서 프로스타글란딘 유사체의 장점은 녹내장 치료제 시장 규모 확대의 원인으로 작용하고 있습니다.

시장은 적응증에 따라 개방각 녹내장, 폐쇄각 녹내장, 기타로 분류됩니다. 개방각 녹내장 부문은 2023년에 가장 큰 녹내장 치료제 시장 점유율을 차지할 것으로 예상되며, 2023-2031년 가장 높은 CAGR을 나타낼 것으로 예측됩니다. 개방각 녹내장은 녹내장의 가장 흔한 형태이며, 약 95%의 사람들이 이 질환을 앓고 있습니다. 처음에는 아무런 증상이 나타나지 않습니다. 그러나 어느 시점에 이르면 치료하지 않으면 측면(주변부) 시야를 잃기 시작하여 실명에 달할 수 있습니다.

시장은 유통 채널별로 병원 약국, 소매 약국, 온라인 약국으로 구분되며, 2023년에는 병원 약국 부문이 시장을 장악할 것으로 예상됩니다.

녹내장 치료제 시장 지역적 개요

녹내장 치료제 시장은 북미(미국, 캐나다, 멕시코), 유럽(스페인, 영국, 독일, 프랑스, 이탈리아, 기타 유럽), 아시아태평양(한국, 중국, 인도, 일본, 호주, 기타 아시아태평양), 중동 및 아프리카(남아프리카, 사우디아라비아, 아랍에미리트, 기타 중동 및 아프리카), 중남미(브라질, 아르헨티나, 기타 중남미)를 대상으로 합니다. 아랍에미리트, 기타 중동 및 아프리카), 중남미(브라질, 아르헨티나, 기타 중남미)입니다. 아시아태평양은 2023-2031년 가장 빠른 CAGR을 나타낼 것으로 예상됩니다. 아시아태평양의 녹내장 치료제 시장 성장에는 새로운 녹내장 치료제 개발을 위한 진행 중인 임상 연구와 이 지역의 의료비 지출 증가 등의 요인이 기여하고 있습니다. 북미는 2023년 매출액 기준으로 가장 큰 녹내장 치료제 시장 점유율을 차지할 것으로 예상됩니다.

녹내장 치료제 시장 - 주요 시장 역학
시장 성장 촉진요인
- 녹내장 이환율의 증가
- 제품 출시, 제휴, 인수의 증가
시장 성장 억제요인
- 복약 컴플라이언스 문제
시장 기회
- 웨어러블 기술의 개발
향후 동향
- 새로운 약물전달 방법의 개발
촉진요인과 억제요인의 영향

제6장 녹내장 치료제 시장 : 세계 시장 분석

녹내장 치료제 시장 매출, 2021-2031년
녹내장 치료제 시장 예측 분석

제7장 녹내장 치료제 시장 분석 - 약제 클래스별

β 차단약
α 아드레날린 작용제
Prostaglandins Analogues
탄산탈수소효소 저해제
병용약
기타

제8장 녹내장 치료제 시장 분석 - 적응증별

개방각 녹내장
폐쇄 우각 녹내장
기타

제9장 녹내장 치료제 시장 분석 - 유통 채널별

병원 약국
소매 약국
온라인 약국

제10장 녹내장 치료제 시장 - 지역 분석

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 아시아태평양의 기타 국가
중동 및 아프리카
- 사우디아라비아
- 남아프리카공화국
- 아랍에미리트
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제11장 녹내장 치료제 시장 - 업계 상황

녹내장 치료제 시장의 성장 전략
유기적 성장 전략
무기적 성장 전략

제12장 기업 개요

Alcon AG
AbbVie Inc
Bausch & Lomb Inc
Fera Pharmaceuticals, LLC
Viatris Inc
Novartis AG
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Thea Pharma Inc
Santen Pharmaceutical Co., Ltd.

제13장 부록

KSA 24.09.23

The glaucoma therapeutics market was valued at US$ 6.24 billion in 2023 and is expected to reach US$ 8.02 billion by 2031; it is estimated to record a CAGR of 3.2% during 2023-2031.

Key factors driving the market growth are the growing prevalence of glaucoma, rising awareness and early diagnosis of the disease, and increasing product launches are expected to drive the market growth. However, compliance issues with medication regimens and the high cost of treatments hinder the glaucoma therapeutics market growth.

Market Trends of the Glaucoma Therapeutics Market:

The gradual damage of the optic nerve-typically associated with high pressure inside the eye (intraocular pressure)-predominantly due to aging can lead to a group of eye diseases called Glaucoma, which can eventually result in irreversible blindness. One of the most common treatments for glaucoma is to reduce intraocular pressure by using eye drops. However, patient adherence to these eye drops can be challenging, and inadequate patient education can impede treatment success. Additionally, ocular hypotensive drugs can cause local and systemic side effects that may further complicate the treatment. Rising focus on the development of improved formulations with enhanced stability, longer circulation times, and targeted binding properties is likely to add novel products to the market. Recent advancements in glaucoma therapeutics have revolutionized the available treatments in the market. The use of nanoparticles with suitable structures and superior binding capabilities facilitates the bioavailability and efficacy of the drug. Sustained-release (SR) implants and other innovative drug delivery systems offer improved patient compliance and reduced side effects compared to conventional eye drops. Several companies are developing SR drug delivery systems as an alternative to topical delivery to potentially overcome barriers in treating POAG. As per the article published in PubMed Central in 2022, the only approved SR therapy for POAG by the Food and Drug Administration (FDA) is Bimatoprost SR (DurystaTM) from Allergan plc. Other SR therapies including bimatoprost ocular ring (Allergan), iDose (Glaukos Corporation), ENV515 (Envisia Therapeutics), OTX-TP (Ocular Therapeutix), OTX-TIC (Ocular Therapeutix), and latanoprost free acid SR (PolyActiva) are under investigation. SR drug delivery technology in POAG management may shift treatment paradigms and dramatically improve outcomes. Therefore, the development of novel drug delivery methods and combination therapies is likely to remain a key trend in the glaucoma therapeutics market.

Glaucoma therapeutics Market: Segmental Overview

The glaucoma therapeutics market is segmented on the basis of drug class, indication, and distribution channel.

By drug class, the market is divided into beta blockers, alpha-adrenergic agonists, prostaglandin analogs, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandin analogs segment held a larger market share in 2023. Prostaglandin analogs are the first-line treatment for high intraocular pressure in glaucoma patients. They offer a once-a-day dosing, a significant reduction in intraocular pressure, and low systemic side effects. Thus, the benefits of prostaglandin analogs are responsible for the expansion of the glaucoma therapeutics market size.

The market, by indication, is segmented into open angle glaucoma, angle closure glaucoma, and others. The open-angle glaucoma segment held the largest glaucoma therapeutics market share in 2023 and is projected to register the highest CAGR from 2023 to 2031. Open-angle glaucoma is the most common form of glaucoma, which affects approximately 95% of individuals. Initially, it does not show any symptoms. However, at some point, an individual may start losing their side (peripheral) vision without treatment, resulting in total blindness.

By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2023.

Glaucoma therapeutics Market: Geographical Overview

The scope of the glaucoma therapeutics market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). Asia Pacific is expected to register the fastest CAGR in the market from 2023 to 2031. Factors such as ongoing clinical studies for developing novel glaucoma therapies, as well as increasing healthcare expenditures in the region, contribute to the glaucoma therapeutics market growth in Asia Pacific. In terms of revenue, North America accounted for the largest glaucoma therapeutics market share in 2023.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Glaucoma Therapeutics Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Glaucoma Therapeutics Market - Key Market Dynamics

5.1 Glaucoma Therapeutics Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Mounting Incidence of Glaucoma Disease
- 5.2.2 Increasing Number of Product Launches, Collaborations, Acquisitions
5.3 Market Restraints
- 5.3.1 Medication Regimen Compliance Issues
5.4 Market Opportunities
- 5.4.1 Development of Wearable Technologies
5.5 Future Trends
- 5.5.1 Development of Novel Drug Delivery Methods
5.6 Impact of Drivers and Restraints:

6. Glaucoma Therapeutics Market - Global Market Analysis

6.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
6.2 Glaucoma Therapeutics Market Forecast Analysis

7. Glaucoma Therapeutics Market Analysis - by Drug Class

7.1 Beta Blockers
- 7.1.1 Overview
- 7.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Alpha Adrenergic Agonists
- 7.2.1 Overview
- 7.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Prostaglandins Analogues
- 7.3.1 Overview
- 7.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Carbonic Anhydrase Inhibitors
- 7.4.1 Overview
- 7.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Combination Drugs
- 7.5.1 Overview
- 7.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. Glaucoma Therapeutics Market Analysis - by Indication

8.1 Open Angle Glaucoma
- 8.1.1 Overview
- 8.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Angle Closure Glaucoma
- 8.2.1 Overview
- 8.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. Glaucoma Therapeutics Market Analysis - by Distribution Channel

9.1 Hospital Pharmacy
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Retail Pharmacy
- 9.2.1 Overview
- 9.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Online Pharmacy
- 9.3.1 Overview
- 9.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

10. Glaucoma Therapeutics Market - Geographical Analysis

10.1 Overview
10.2 North America
- 10.2.1 North America Glaucoma Therapeutics Market Overview
- 10.2.2 North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 10.2.3 North America: Glaucoma Therapeutics Market Breakdown, by Drug Class
  - 10.2.3.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
- 10.2.4 North America: Glaucoma Therapeutics Market Breakdown, by Indication
  - 10.2.4.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
- 10.2.5 North America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.2.5.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
- 10.2.6 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.2.6.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.2.6.2 United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.2.6.2.1 United States: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.2.6.2.2 United States: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.2.6.2.3 United States: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.2.6.3 Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.2.6.3.1 Canada: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.2.6.3.2 Canada: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.2.6.3.3 Canada: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.2.6.4 Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.2.6.4.1 Mexico: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.2.6.4.2 Mexico: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.2.6.4.3 Mexico: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.3 Europe
- 10.3.1 Europe Glaucoma Therapeutics Market Overview
- 10.3.2 Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 10.3.3 Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
  - 10.3.3.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
- 10.3.4 Europe: Glaucoma Therapeutics Market Breakdown, by Indication
  - 10.3.4.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
- 10.3.5 Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.3.5.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
- 10.3.6 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.3.6.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.3.6.2 Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.6.2.1 Germany: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.3.6.2.2 Germany: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.3.6.2.3 Germany: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.3.6.3 France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.6.3.1 France: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.3.6.3.2 France: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.3.6.3.3 France: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.3.6.4 United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.6.4.1 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.3.6.4.2 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.3.6.4.3 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.3.6.5 Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.6.5.1 Italy: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.3.6.5.2 Italy: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.3.6.5.3 Italy: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.3.6.6 Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.6.6.1 Spain: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.3.6.6.2 Spain: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.3.6.6.3 Spain: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.3.6.7 Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.6.7.1 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.3.6.7.2 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.3.6.7.3 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.4 Asia Pacific
- 10.4.1 Asia Pacific Glaucoma Therapeutics Market Overview
- 10.4.2 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 10.4.3 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Drug Class
  - 10.4.3.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
- 10.4.4 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Indication
  - 10.4.4.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
- 10.4.5 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.4.5.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
- 10.4.6 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.4.6.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.4.6.2 China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.6.2.1 China: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.4.6.2.2 China: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.4.6.2.3 China: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.4.6.3 Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.6.3.1 Japan: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.4.6.3.2 Japan: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.4.6.3.3 Japan: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.4.6.4 India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.6.4.1 India: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.4.6.4.2 India: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.4.6.4.3 India: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.4.6.5 Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.6.5.1 Australia: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.4.6.5.2 Australia: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.4.6.5.3 Australia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.4.6.6 South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.6.6.1 South Korea: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.4.6.6.2 South Korea: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.4.6.6.3 South Korea: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.4.6.7 Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.6.7.1 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.4.6.7.2 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.4.6.7.3 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.5 Middle East and Africa
- 10.5.1 Middle East and Africa Glaucoma Therapeutics Market Overview
- 10.5.2 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 10.5.3 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
  - 10.5.3.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
- 10.5.4 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication
  - 10.5.4.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
- 10.5.5 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.5.5.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
- 10.5.6 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.5.6.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.5.6.2 Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.6.2.1 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.5.6.2.2 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.5.6.2.3 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.5.6.3 South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.6.3.1 South Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.5.6.3.2 South Africa: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.5.6.3.3 South Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.5.6.4 United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.6.4.1 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.5.6.4.2 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.5.6.4.3 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.5.6.5 Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.6.5.1 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.5.6.5.2 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.5.6.5.3 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.6 South and Central America
- 10.6.1 South and Central America Glaucoma Therapeutics Market Overview
- 10.6.2 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 10.6.3 South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
  - 10.6.3.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
- 10.6.4 South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication
  - 10.6.4.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
- 10.6.5 South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.6.5.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
- 10.6.6 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.6.6.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.6.6.2 Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.6.6.2.1 Brazil: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.6.6.2.2 Brazil: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.6.6.2.3 Brazil: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.6.6.3 Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.6.6.3.1 Argentina: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.6.6.3.2 Argentina: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.6.6.3.3 Argentina: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.6.6.4 Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.6.6.4.1 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.6.6.4.2 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.6.6.4.3 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

11. Glaucoma Therapeutics Market - Industry Landscape

11.1 Growth Strategies in Glaucoma Therapeutics Market
11.2 Organic Growth Strategies
- 11.2.1 Overview
11.3 Inorganic Growth Strategies
- 11.3.1 Overview

12. Company Profiles

12.1 Alcon AG
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 AbbVie Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Bausch & Lomb Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Fera Pharmaceuticals, LLC
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Viatris Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Novartis AG
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Sun Pharmaceutical Industries Ltd
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Teva Pharmaceutical Industries Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Thea Pharma Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Santen Pharmaceutical Co., Ltd.
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms